1. Most Discussed
  2. Gainers & Losers
NEU $1.30

Latest BTD approval

  1. hottod

    3,229 Posts.
    1,268
    Intercept Pharmaceuticals (ICPT: Nasdaq) is the latest company to be granted Breakthrough Therapy Designation from the FDA.

    Intercept announced after close of Thursday trade that breakthrough designation had been granted for its investigational product obeticholic acid (OCA) for the treatment of patients with nonalcoholic steatohepatitis (NASH) with liver fibrosis.

    Breakthrough therapy designation for OCA was based on clinical efficacy and safety data from two placebo-controlled, Phase 2 clinical trials of OCA, one in 64 patients and the second in 283 patients. Intercept will now be working closely with the FDA to finalise design of its Phase 3 program for the drug.

    ICPT's stock price rose $49.31 (28.89%) in post-market trade, adding just over US$1 billion to Intercept’s market capitalisation.


    http://www.noodls.com/view/118BB84A104684E5DA8EE60CCB1F3140FD2968AB

    https://au.finance.yahoo.com/q?s=ICPT

DISCLAIMER:
Before making any financial decisions based on what you read, always consult an advisor or expert.

The HotCopper website is operated by Report Card Pty Ltd. Any information posted on the website has been prepared without taking into account your objectives, financial situation or needs and as such, you should before acting on the information or advice, consider the appropriateness of the information or advice in relation to your objectives, financial situation or needs. Please be aware that any information posted on this site should not be considered to be financial product advice.

From time to time comments aimed at manipulating other investors may appear on these forums. Posters may post overly optimistic or pessimistic comments on particular stocks, in an attempt to influence other investors. It is not possible for management to moderate all posts so some misleading and inaccurate posts may still appear on these forums. If you do have serious concerns with a post or posts you should report a Terms of Use Violation (TOU) on the link above. Unless specifically stated persons posting on this site are NOT investment advisors and do NOT hold the necessary licence, or have any formal training, to give investment advice.

Top

Thank you for visiting HotCopper

We have detected that you are running ad blocking software.


HotCopper relies on revenue generated from advertisers. Kindly disable your ad blocking software to return to the HotCopper website.

I understand, I have disabled my ad blocker. Let me in!

Need help? Click here for support.